WORLD JOURNAL OF PLASTIC SURGERY
Mon, Nov 3, 2025
[Archive]
Ricardo Grillo *1 
, Sahand Samieirad2 , Bruno Alvarez Quinta Reis1 , Bernardo Correia Lima3 , Fernando Melhem- Elias4
, Sahand Samieirad2 , Bruno Alvarez Quinta Reis1 , Bernardo Correia Lima3 , Fernando Melhem- Elias4
1- Oral and Maxillofacial Surgery Training Program, Foundation of Dentistry - Fundecto, University of São Paulo, São Paulo, Brazil
2- Department of Oral and Maxillofacial Surgery, Mashhad Dental School, Mashhad University of Medical Sciences, Mashhad, Iran.
3- Oral Diagnosis, Dental Radiology and Imaging Postgraduate Program, School of Dentistry, University of São Paulo, São Paulo, Brazil
4- Department of Oral and Maxillofacial Surgery, University of São Paulo School of Dentistry, São Paulo-SP, Brazil.
2- Department of Oral and Maxillofacial Surgery, Mashhad Dental School, Mashhad University of Medical Sciences, Mashhad, Iran.
3- Oral Diagnosis, Dental Radiology and Imaging Postgraduate Program, School of Dentistry, University of São Paulo, São Paulo, Brazil
4- Department of Oral and Maxillofacial Surgery, University of São Paulo School of Dentistry, São Paulo-SP, Brazil.
Abstract: (22 Views)
Semaglutide, a once-weekly GLP-1 receptor agonist, has emerged as a promising therapeutic option for individuals struggling with obesity and type 2 diabetes mellitus (T2DM). Its ability to induce weight loss, reduce appetite, and improve glycemic control has led to its increasing utilization in clinical practice. Semaglutide works by mimicking the action of endogenous GLP-1, leading to enhanced insulin secretion, decreased glucagon secretion, and delayed gastric emptying
Type of Study: Letter to Editor |
Subject:
Special
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
